Investors Capital Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Investors Capital Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,225	Closed	-$427K	–	736
2015 Q2	$427K	Sell	5,225 -2,275	-30%	-$223K	0.08%	363
2015 Q1	$694K	Hold	7,500	–	–	0.13%	232
2014 Q4	$303K	Buy	+7,500	New	+$230K	0.06%	440

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Investors Capital Advisory Services's ESPR Position: Q3 2015 in Review

Investors Capital Advisory Services sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 5,225 shares — an estimated $427K sold.

Investors Capital Advisory Services first reported a position in ESPR in Q4 2014 and held it in 3 quarters. The position peaked at $694K in Q1 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

Investors Capital Advisory Services reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 5,225 Esperion Therapeutics shares in Q3 2015, an estimated $427K.
Investors Capital Advisory Services first reported a position in Esperion Therapeutics in Q4 2014 and held it in 3 quarters.
Investors Capital Advisory Services's Esperion Therapeutics position peaked at $694K in Q1 2015.
121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Investors Capital Advisory Services's 13F filing for Q3 2015, filed 17 Nov 2015.